SOCIETE DE PROMOTION PHARMACEUTIQUE DU MAGHREB S.A. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 985.7 MAD | +5.99% |
|
+6.79% | -1.43% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2021 | 630M 62.87M | Sales 2022 | 705M 70.26M | Capitalization | 1.07B 106M |
|---|---|---|---|---|---|
| Net income 2021 | 69M 6.88M | Net income 2022 | 75M 7.48M | EV / Sales 2021 | 1.48 x |
| Net cash position 2021 | 205M 20.45M | Net cash position 2022 | 56.78M 5.66M | EV / Sales 2022 | 1.44 x |
| P/E ratio 2021 |
16.5
x | P/E ratio 2022 |
14.2
x | Employees | - |
| Yield 2021 |
3.51% | Yield 2022 |
3.75% | Free-Float | 5.88% |
More Fundamentals
* Assessed data
More news
More news
| 1 day | +5.99% | ||
| 1 week | +6.79% | ||
| Current month | +5.99% | ||
| 1 month | +4.74% | ||
| 3 months | +3.65% | ||
| 6 months | -1.43% | ||
| Current year | -1.43% |
1 week
930.00
985.70
1 month
921.00985.70
Current year
921.001 008.00
1 year
921.001 110.00
3 years
800.001 226.00
5 years
690.001 226.00
10 years
634.001 690.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | - | |
Said El Bouachi
DFI | Director of Finance/CFO | - | - |
Amine Alaoui
PRN | Corporate Officer/Principal | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ma’moun Araidah
CHM | Chairman | - | - |
Khalid Janahi
BRD | Director/Board Member | - | - |
Issam Maguiri
BRD | Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-06 | 985 | -0.07% | 3 |
| 24-05-02 | 985.7 | +5.99% | 55 |
| 24-04-30 | 930 | +0.54% | 1 |
| 24-04-29 | 925 | +0.22% | 5 |
End-of-day quote Casablanca S.E., May 01, 2024
More quotes
Promopharm (Société de Promotion Pharmaceutique du Maghreb) specializes in manufacturing and marketing pharmaceutical, para-pharmaceutical, and cosmetic products. The group also offers subcontractor manufacturing services for pharmaceutical specialties for Moroccan and foreign laboratories. The group's activity is organized primarily around 2 areas:
- sales of drugs: products manufactured under its own name and under license;
- importing and sales of semi-finished products.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -1.43% | 98.07M | |
| +21.41% | 43.48B | |
| +20.67% | 22.65B | |
| +14.56% | 14.73B | |
| +14.21% | 13.79B | |
| +48.11% | 12.04B | |
| -8.37% | 7.08B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +11.90% | 5.47B |
- Stock Market
- Equities
- PRO Stock